Trump's Medicaid Drug Price Pilot
Analysis based on 6 articles · First reported Apr 20, 2026 · Last updated Jun 30, 2026
The market impact is mixed. Large pharmaceutical companies have already agreed to lower prices, but mid-sized and smaller drugmakers are hesitant, potentially limiting the overall savings. Legal challenges from industry groups like Pharmaceutical Research and Manufacturers of America and Hong Kong Biotechnology Organization against the United States — Centers for Medicare & Medicaid Services' authority could create uncertainty and affect future drug pricing policies.
President Donald Trump's administration launched a United States — Medicaid pilot program aimed at lowering U.S. prescription drug prices to levels comparable to other developed countries. While 17 large global drugmakers signed deals, mid-sized and smaller pharmaceutical companies, such as Ionis Pharmaceuticals, have shown tepid interest due to different business models and perceived limited upside. Only Astellas Pharma among 19 contacted mid-sized companies confirmed participation. The United States — Centers for Medicare & Medicaid Services (CMS) expects $64.3 billion in federal and state savings over 10 years, but this is speculative. Industry groups like Pharmaceutical Research and Manufacturers of America and Hong Kong Biotechnology Organization are challenging the legality of these programs, including potential mandatory United States — Medicare pilot programs, arguing they exceed CMS's authority and violate constitutional principles. This situation highlights the challenges in implementing broad drug pricing reforms and the potential for legal battles.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard